Saad Z. Usmani, MD, MBA, FACP

An overview of treatment regimens available for patients with newly diagnosed multiple myeloma who are ineligible for stem cell transplantation.

The current rationale for managing a patient with newly diagnosed multiple myeloma with consolidation therapy post-transplant.

Usmani detailed the primary results from CARTITUDE-1, focusing on overall response rate and stringent complete responses.

Usmani highlighted the FORTE study as one of the trials investigating the high-risk cohort of patients.

Usmani discussed the common adverse events observed from CARTITUDE-1, including hematologic events and cytokine release syndrome.

Usmani noted the strong overall response and stringent complete response rates observed with ciltacabtagene autoleucel for multiple myeloma at a median follow-up of 18 months.